Monte Carlo Calculations and Measurement of Photon Beams Shaped by Multileaf Collimators in Radiation Therapy

PhDA model based on Monte Carlo techniques is developed to transport ionising radiation through the radiation head of a 6MV linear accelerator fitted with multileaf collimators Major emphasis is given to the detailed geometrical descriptiqn of the multileaf collimator. The model produces dose distributions in water from photon beams defined by the jaws and the multileaf collimator. The model accounts for contaminant electrons in the photon beam, off-axis x-ray radiation originating at the collimator and the transmission and penumbra effects of the side planes and front face of the leaves in the multileaf collimator Dose distributions in water calculated by the model are compared with experiment using lonisation chambers, diodes and film and found to be within 1 5% The transmission and the penumbra of the multileaf collimator leaves calculated by the Monte Carlo model are compared with experiment and found to be in good agreemen

Threat Landscape and Good Practice Guide for Software Defined Networks/5G

5G represents the next major phase of mobile telecommunication systems and network architectures beyond the current 4G standards, aiming at extreme broadband and ultra-robust, low latency connectivity, to enable the programmable connectivity for the Internet of Everything2. Despite the significant debate on the technical specifications and the technological maturity of 5G, which are under discussion in various fora3, 5G is expected to affect positively and significantly several industry sectors ranging from ICT to industry sectors such as car and other manufacturing, health and agriculture in the period up to and beyond 2020. 5G will be driven by the influence of software on network functions, known as Software Defined Networking (SDN) and Network Function Virtualization (NFV). The key concept that underpins SDN is the logical centralization of network control functions by decoupling the control and packet forwarding functionality of the network. NFV complements this vision through the virtualization of these functionalities based on recent advances in general server and enterprise IT virtualization. Considering the technological maturity of the technologies that 5G can leverage on, SDN is the one that is moving faster from development to production. To realize the business potential of SDN/5G, a number of technical issues related to the design and operation of Software Defined Networks need to be addressed. Amongst them, SDN/5G security is one of the key issues, that needs to be addressed comprehensively in order to avoid missing the business opportunities arising from SDN/5G. In this report, we review threats and potential compromises related to the security of SDN/5G networks. More specifically, this report contains a review of the emerging threat landscape of 5G networks with particular focus on Software Defined Networking. It also considers security of NFV and radio network access. To provide a comprehensive account of the emerging threat SDN/5G landscape, this report has identified related network assets and the security threats, challenges and risks arising for these assets. Driven by the identified threats and risks, this report has also reviewed and identified existing security mechanisms and good practices for SDN/5G/NFV, and based on these it has analysed gaps and provided technical, policy and organizational recommendations for proactively enhancing the security of SDN/5G

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis.

Objective: To assess whether canakinumab, a monoclonal antibody against IL-1β approved for autoinflammatory diseases, is effective as target-specific therapy in patients with sporadic inclusion body myositis (sIBM). Methods: Because in sIBM IL-1β colocalizes with amyloid precursor protein and upregulates amyloid aggregates enhancing degeneration, targeting IL-1β with canakinumab may arrest disease progression. On this basis, 5 ambulatory patients with sIBM participated in an institutional review board--approved open-labeled study with 150 mg canakinumab [4 bimonthly, then monthly subcutaneous injections] for a mean period of 15.8 months. Patients were assessed bimonthly with a manual dynamometer in 12 proximal and distal muscles and with grip force (GF) in both hands. Total muscle strength (TMS) was expressed in kilograms. Efficacy was defined as \u3e15% increased strength after 12 months. Results: Patient 1 stopped at month 5 because of 23% loss in TMS and 32.35% in GF; patient 2 showed 37.1% increase in TMS and 13% in GF by month 9; patient 3 exhibited 26.7% reduction in TMS and 10% in GF at month 33; patient 4 showed 6.5% reduction in TMS and 1.6% in GF after 15 months, denoting relative stability; and patient 5 showed 30.4% loss in TMS and 20.8% in GF after 18 months. In patients 2 and 4, in whom 3-year longitudinal data were available, no effect on disease progression was noted. Conclusions: In this long-term, open-label study, canakinumab showed small, but not clinically appreciable, stabilizing benefits in 2 of 5 patients with sIBM over 1 year, was ineffective in 2 others, and might have worsened one. No patient improved. Classification of evidence: This study provides Class IV evidence that canakinumab was ineffective for patients with sIBM

Incidence and prevalence of major central nervous system involvement in Systemic Lupus Erythematosus: A 3-year prospective study of 370 patients

Background: The incidence and prevalence of CNS involvement in SLE remains unclear owing to conflicting results in the published studies. The aim of the study was to evaluate the incidence and prevalence of major definite CNS events in SLE patients. Methods: 370 SLE patients with no previous history of CNS involvement were prospectively evaluated in a tertiary hospital referral center for 3 years. Major CNS manifestations were codified according to ACR definitions, including chorea, aseptic meningitis, psychosis, seizures, myelopathy, demyelinating syndrome, acute confusional state and strokes. Minor CNS events were excluded. ECLAM and SLEDAI-SELENA Modification scores were used to evaluate disease activity and SLICC/ACR Damage Index was used to assess accumulated damage. Results: 16/370 (4.3%) patients presented with a total of 23 major CNS events. These included seizures (35%), strokes (26%), myelopathy (22%), optic neuritis (8.7%), aseptic meningitis (4.3%) and acute psychosis (4.3%). Incidence was 7.8/100 person years. Among hospitalizations for SLE, 13% were due to CNS manifestations. Epileptic seizures were associated with high disease activity, while myelopathy correlated with lower disease activity and NMO-IgG antibodies (P#0.05). Stroke incidence correlated with APS coexistence (P = 0.06). Overall, CNS involvement correlated with high ECLAM and SLEDAI scores (P,0.001). Conclusions: Clinically severe CNS involvement is rare in SLE patients, accounting for 7.8/100 person years. CNS involvement correlates with high disease activity and coexistence of specific features that define the respective CNS syndromes

AGRICULTURAL POLICY REFORM IN THE WTO: THE ROAD AHEAD

Agricultural trade barriers and producer subsidies inflict real costs, both on the countries that use these policies and on their trade partners. Trade barriers lower demand for trade partners' products, domestic subsidies can induce an oversupply of agricultural products which depresses world prices, and export subsidies create increased competition for producers in other countries. Eliminating global agricultural policy distortions would result in an annual world welfare gain of $56 billion. High protection for agricultural commodities in the form of tariffs continues to be the major factor restricting world trade. In 2000, World Trade Organization (WTO) members continued global negotiations on agricultural policy reform. To help policymakers and others realize what is at stake in the global agricultural negotiations, this report quantifies the costs of global agricultural distortions and the potential benefits of their full elimination. It also analyzes the effects on U.S. and world agriculture if only partial reform is achieved in liberalizing tariffs, tariff-rate quotas (limits on imported goods), domestic support, and export subsidies.Agricultural and Food Policy, International Relations/Trade,